Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy

YILDIRIM, HASAN; GÜVEN, DENİZ; AKTEPE, OKTAY; TABAN, HAKAN; YILMAZ, FERİDE; YAŞAR, SERKAN; AKTAŞ, BURAK; GÜNER, GÜRKAN; DİZDAR, ÖMER; AKSOY, SERCAN; ERMAN, MUSTAFA; YALÇIN, ŞUAYİB; Kilickap, Saadettin

doi:10.14744/ejmo.2022.78280

Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy

YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., ...More

EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, vol.6, no.1, pp.59-63, 2022 (ESCI, TRDizin)

Publication Type: Article / Article
Volume: 6 Issue: 1
Publication Date: 2022
Doi Number: 10.14744/ejmo.2022.78280
Journal Name: EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
Page Numbers: pp.59-63
Keywords: Hyperprogressive disease, immun checkpoint inhibitors, immunotherapy, PILE score
Hacettepe University Affiliated: Yes

Abstract

Objectives: Although immune checkpoint inhibitors (ICIs) became a vital part of cancer care, many patients do not respond to treatment. In this group, a few of the patients with a hyperprogressive disease (HPD) have shorter overall survival (OS) compared with those having a progressive disease (PD). Therefore, biomarkers are needed to differentiate HPD and PD.